Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute
August 29, 2023 14:52 ET
|
Spark Biomedical
DALLAS, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aug. 29, 2023 — Spark Biomedical, Inc., a Dallas-based pioneer in wearable neurostimulation technology, was awarded a $1.15M Phase II grant to...
Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment
August 08, 2023 12:05 ET
|
Spark Biomedical
DALLAS, TX, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical Launches Telehealth Services for Sparrow Ascent, Improving Patient Access to Opioid Withdrawal Treatment August 8, 2023, Dallas, TX...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
July 11, 2023 14:54 ET
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
July 11, 2023 14:38 ET
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Spark Biomedical’s second-generation device, Sparrow® Ascent, Receives FDA Clearance for Opioid Withdrawal Relief in Adults
July 11, 2023 14:31 ET
|
Spark Biomedical
DALLAS, TX, July 11, 2023 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc., a leading innovator in wearable neurostimulation development, is proud to announce that its next-generation, groundbreaking...
Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease
July 06, 2023 14:37 ET
|
Spark Biomedical
DALLAS, TX and MANHASSET, NY, July 06, 2023 (GLOBE NEWSWIRE) -- Five Liters, a Dallas-based wearable neuromodulation company, is embarking on a series of groundbreaking first-in-human studies to...
Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal
January 17, 2023 12:47 ET
|
Spark Biomedical
GALVESTON, Texas, Jan. 17, 2023 (GLOBE NEWSWIRE) -- A multi-year clinical trial at the University of Texas Medical Branch (UTMB) and Medical University of South Carolina (MUSC) will examine the use...
Feinstein Institutes for Medical Research and Spark Biomedical, Inc. advance bioelectric medicine designed to stem excessive blood loss
June 02, 2022 11:00 ET
|
Spark Biomedical
DALLAS, TX and MANHASSET, NY, June 02, 2022 (GLOBE NEWSWIRE) -- Spark Biomedical, a leader in wearable neurostimulation solutions, announced today a collaboration with The Feinstein Institutes for...
Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome
March 03, 2022 11:22 ET
|
Spark Biomedical
Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...
Spark Biomedical, Inc. Granted $2.49M from the National Institutes of Health for a Clinical Trial Looking at Extended Use of Wearable Neurostimulation in Opioid Use Disorder Treatment
November 16, 2021 11:00 ET
|
Spark Biomedical
Dallas, TX, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. has been helping patients overcome acute opioid withdrawal using its Sparrow Therapy System — Transcutaneous Auricular...